Secondary Prophylaxis With Bioequivalent Generic Letermovir in Haploidentical Hematopoietic Stem Cell Transplantation: A Case Report. (PubMed, Cureus) - Feb 10, 2026 - "Cytomegalovirus (CMV) reactivation poses a significant risk post-allogeneic hematopoietic stem cell transplantation (HSCT), particularly in high-risk settings. The episode was successfully managed in the outpatient setting with oral valganciclovir. This case highlights the importance of sustained CMV prophylaxis and the role of accessible antiviral strategies in optimizing transplant outcomes."
Journal • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Cytomegalovirus Infection • Hematological Malignancies • Leukemia • Oncology • Transplant Rejection • Transplantation
|
|
Abhijit Baheti; Suyash Bharat
|